Jade Biosciences, Inc. (JBIO)
NASDAQ: JBIO · Real-Time Price · USD
9.39
-0.12 (-1.26%)
Jul 18, 2025, 3:33 PM - Market open
Company Description
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
The company was incorporated in 2024 and is headquartered in Waltham, Massachusetts.
Jade Biosciences, Inc.
| Country | United States |
| Founded | 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
| CEO | Tom Frohlich |
Contact Details
Address: 221 Crescent Street Building 23, Suite 105 Waltham, Massachusetts 02453 United States | |
| Phone | 916 322 1700 |
| Website | jadebiosciences.com |
Stock Details
| Ticker Symbol | JBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000947559 |
| CUSIP Number | 008064206 |
| ISIN Number | US0080642061 |
Key Executives
| Name | Position |
|---|---|
| Tom Frohlich | Chief Executive Officer and Director |
| Jonathan Quick | Senior Vice President of Finance |
| Dr. Andrew James King D.V.M., Ph.D. | Chief Scientific Officer and Head of Research & Development |
| Elizabeth Balta | General Counsel and Corporate Secretary |
| Lori Stewart | Senior Vice President of People |
| Dr. Hetal Kocinsky M.D. | Chief Medical Officer |
| Dr. Jason Wright Ph.D. | Senior Vice President, Chemistry, Manufacturing and Controls |
| Valerie Fauvelle | Senior Vice President of Regulatory and Quality |
| Amy Sullivan | Senior Vice President of Development Operations |
| Sandy Lewis | Senior Vice President, Biometrics and Clinical Strategy |